Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development
AstraZeneca Plc
NFlection Therapeutics Inc
Pfizer Inc
SpringWorks Therapeutics Inc
Vyriad Inc
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drug Profiles
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirdametinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NFX-179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurofibromatoses Type I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Product Development Milestones
Featured News & Press Releases
Apr 14, 2020: KOSELUGO (selumetinib) approved for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas in pediatric patients, available from Onco360
Apr 13, 2020: FDA approves AstraZeneca’s Koselugo to treat rare genetic disorder
Apr 10, 2020: FDA Approves First Ever Treatment for Neurofibromatosis
Mar 18, 2020: In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1
Nov 15, 2019: FDA grants priority review to tumour drug selumetinib
Oct 28, 2019: Selumetinib shows clinical benefit in adult patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
Oct 25, 2019: SpringWorks starts Phase IIb trial of mirdametinib in NF1-PN
Jul 30, 2019: European Commission grants Orphan Drug Desigtion for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the treatment of Neurofibromatosis Type 1
Jun 03, 2019: SpringWorks Therapeutics Announces FDA Fast Track Desigtion for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1
Apr 01, 2019: FDA grants AstraZeneca-Merck’s selumetinib breakthrough therapy desigtion
Dec 10, 2012: Study Identifies Targeted Molecular Therapy For Untreatable NF1 Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, H1 2020
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by NFlection Therapeutics Inc, H1 2020
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Pfizer Inc, H1 2020
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by SpringWorks Therapeutics Inc, H1 2020
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Vyriad Inc, H1 2020
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, H1 2020